Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Applications are invited for the prestigious role of Director of the MRC Weatherall Institute of Molecular Medicine (MRC WIMM).

The appointee will provide inspiring scientific and strategic leadership for this world leading research institute within the Radcliffe Department of Medicine (RDM). S/he will be responsible for the overall management of the Institute including pursuing a strong vision for translational research into human health, developing scientific infrastructure, maintaining local, national and international relationships which contribute to the profile of the Institute and helping to nurture working relationships with sponsors, including the Institute’s major sponsor the Medical Research Council (MRC). A key responsibility will be to develop synergies across the MRC’s Molecular Haematology and Human Immunology Units and other science within the MRC WIMM. 

The MRC WIMM’s mission is to undertake internationally leading research into the processes underlying normal cell and molecular biology, to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases and to translate this research to improve human health.

The successful candidate will be an internationally leading and innovative scientist of the highest calibre with exceptional leadership and management skills, whose ultimate research goal is to improve human health. S/he will ensure that the environment of academic excellence within the MRC WIMM and RDM is maintained.

The appointee will hold a PhD/DPhil, MD or equivalent with significant post-qualification research experience.

Applications for this vacancy are to be made online. To apply for this role and for further details, including a job description and selection criteria, please click on the link below:-

https://www.recruit.ox.ac.uk/pls/hrisliverecruit/erq_jobspec_version_4.jobspec?p_id=137797

The closing date for this position is 12.00 midday on Monday 3rd December 2018.

Applicants for this position may also be interested in applying for the role of Director of the MRC Molecular Haematology Unit which is also being advertised here and can be held in conjunction with the position of Institute Director.

Applications are particularly welcome from women and black and minority ethnic candidates, who are under-represented in academic posts in Oxford

Similar stories

Many Long COVID patients continue to experience symptoms one year after hospital discharge

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Study links the onset of circulation to changes in metabolism affecting blood stem cell development

A new paper published in Cell Reports by the de Bruijn Group indicates that the onset of circulation triggers a metabolic switch associated with the maturation of haematopoietic stem cells.

Mohsin Badat receives ASH-BSH Abstract Achievement Award

Dr Mohsin Badat, a Clinical Training Research Fellow from the Higgs and Davies Groups has been awarded the ASH-BSH Abstract Achievement Award by the American Society of Haematology and the British Society of Haematology.

Iron integral to the development of life on Earth – and the possibility of life on other planets

A collaboration between researchers at the MRC WIMM and Department of Earth Sciences uncovers the importance of iron for the development of complex life on Earth.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.